Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CGEM NASDAQ:DNLI NASDAQ:EWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.77-0.8%$22.26$19.69▼$28.35$4.45B0.81.62 million shs1.15 million shsCGEMCullinan Therapeutics$17.81+1.0%$15.19$5.68▼$19.43$1.08B-0.011.38 million shs771,684 shsDNLIDenali Therapeutics$25.74-0.3%$21.24$12.58▼$26.80$4.10B0.961.89 million shs1.33 million shsEWTXEdgewise Therapeutics$40.10+1.4%$35.48$12.30▼$43.93$4.26B0.271.52 million shs511,246 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+2.57%+20.45%+16.35%+23.96%CGEMCullinan Therapeutics0.00%-4.18%+30.50%+18.16%+125.74%DNLIDenali Therapeutics0.00%+1.02%+32.33%+33.28%+75.77%EWTXEdgewise Therapeutics0.00%-4.58%+11.15%+20.50%+205.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.77-0.8%$22.26$19.69▼$28.35$4.45B0.81.62 million shs1.15 million shsCGEMCullinan Therapeutics$17.81+1.0%$15.19$5.68▼$19.43$1.08B-0.011.38 million shs771,684 shsDNLIDenali Therapeutics$25.74-0.3%$21.24$12.58▼$26.80$4.10B0.961.89 million shs1.33 million shsEWTXEdgewise Therapeutics$40.10+1.4%$35.48$12.30▼$43.93$4.26B0.271.52 million shs511,246 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+2.57%+20.45%+16.35%+23.96%CGEMCullinan Therapeutics0.00%-4.18%+30.50%+18.16%+125.74%DNLIDenali Therapeutics0.00%+1.02%+32.33%+33.28%+75.77%EWTXEdgewise Therapeutics0.00%-4.58%+11.15%+20.50%+205.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$32.5926.46% UpsideCGEMCullinan Therapeutics 2.63Moderate Buy$32.0079.67% UpsideDNLIDenali Therapeutics 2.81Moderate Buy$34.2533.06% UpsideEWTXEdgewise Therapeutics 2.80Moderate Buy$47.6418.79% UpsideCurrent Analyst Ratings BreakdownLatest CGEM, EWTX, ACAD, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026EWTXEdgewise Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $51.006/30/2026ACADACADIA Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2026ACADACADIA Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $30.006/29/2026ACADACADIA Pharmaceuticals Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.006/29/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $35.006/29/2026ACADACADIA Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.006/22/2026DNLIDenali Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$41.006/22/2026DNLIDenali Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/17/2026EWTXEdgewise Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $59.006/17/2026EWTXEdgewise Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$20.00 ➝ $32.006/16/2026EWTXEdgewise Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B4.12$0.88 per share29.27$7.25 per share3.55CGEMCullinan TherapeuticsN/AN/AN/AN/A$6.92 per shareN/ADNLIDenali Therapeutics$330.53M12.36N/AN/A$6.91 per share3.73EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.7129.9718.7134.30%9.61%7.07%8/5/2026 (Estimated)CGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)EWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)Latest CGEM, EWTX, ACAD, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48CGEMCullinan TherapeuticsN/A10.2810.28DNLIDenali Therapeutics0.019.289.28EWTXEdgewise TherapeuticsN/A22.6122.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CGEMCullinan Therapeutics86.31%DNLIDenali Therapeutics92.92%EWTXEdgewise TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%CGEMCullinan Therapeutics8.60%DNLIDenali Therapeutics12.50%EWTXEdgewise Therapeutics21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableCGEM, EWTX, ACAD, and DNLI HeadlinesRecent News About These CompaniesAlan Russell Sells 200,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) StockJuly 4 at 4:13 AM | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Insider Sells 200,000 Shares of StockJuly 3 at 5:51 AM | insidertrades.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesJuly 1, 2026 | prnewswire.comIs Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?June 29, 2026 | insidermonkey.comEdgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial DataJune 26, 2026 | insidermonkey.comEdgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy TranscriptJune 17, 2026 | seekingalpha.comEdgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - SlideshowJune 17, 2026 | seekingalpha.comWhy Edgewise Therapeutics, Inc.’s (EWTX) Stock Is Down 9.20%June 16, 2026 | aaii.comAEdgewise Therapeutics Reports Improvements In Heart Drug TrialJune 16, 2026 | benzinga.comSpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fallJune 16, 2026 | finance.yahoo.comEdgewise falls after trial data for heart disease therapyJune 16, 2026 | seekingalpha.comEdgewise shares slip after heart-disease drug trial data disappoints investorsJune 16, 2026 | reuters.comEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)June 16, 2026 | prnewswire.comEdgewise Therapeutics Shareholders Back Board and GovernanceJune 5, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Context Therapeutics (CNTX), IDEAYA Biosciences (IDYA) and Edgewise Therapeutics (EWTX)June 5, 2026 | theglobeandmail.comEdgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 AdvancementJune 4, 2026 | seekingalpha.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesJune 3, 2026 | prnewswire.comAssessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price MoveJune 2, 2026 | finance.yahoo.comEdgewise Therapeutics Stock Hits Record High on $2.65B Servier DealJune 2, 2026 | zacks.comHow Edgewise sweetened its coffers by $1.55 billion, and removed a key overhangJune 1, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGEM, EWTX, ACAD, and DNLI Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$25.77 -0.20 (-0.77%) Closing price 04:00 PM EasternExtended Trading$25.35 -0.42 (-1.63%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Cullinan Therapeutics NASDAQ:CGEM$17.81 +0.18 (+1.02%) Closing price 04:00 PM EasternExtended Trading$17.86 +0.05 (+0.31%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Denali Therapeutics NASDAQ:DNLI$25.74 -0.09 (-0.35%) Closing price 04:00 PM EasternExtended Trading$25.68 -0.06 (-0.25%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Edgewise Therapeutics NASDAQ:EWTX$40.10 +0.54 (+1.37%) Closing price 04:00 PM EasternExtended Trading$39.24 -0.86 (-2.14%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
